These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 16830009

  • 1. Progress towards a Leishmania vaccine.
    Tabbara KS.
    Saudi Med J; 2006 Jul; 27(7):942-50. PubMed ID: 16830009
    [Abstract] [Full Text] [Related]

  • 2. Cutaneous leishmaniasis: progress towards a vaccine.
    Launois P, Tacchini-Cottier F, Kieny MP.
    Expert Rev Vaccines; 2008 Oct; 7(8):1277-87. PubMed ID: 18844599
    [Abstract] [Full Text] [Related]

  • 3. The immunology of Leishmania infection and the implications for vaccine development.
    Vanloubbeeck Y, Jones DE.
    Ann N Y Acad Sci; 2004 Oct; 1026():267-72. PubMed ID: 15604504
    [Abstract] [Full Text] [Related]

  • 4. Live attenuated Leishmania vaccines: a potential strategic alternative.
    Silvestre R, Cordeiro-da-Silva A, Ouaissi A.
    Arch Immunol Ther Exp (Warsz); 2008 Oct; 56(2):123-6. PubMed ID: 18373245
    [Abstract] [Full Text] [Related]

  • 5. Leishmania vaccines: progress and problems.
    Kedzierski L, Zhu Y, Handman E.
    Parasitology; 2006 Oct; 133 Suppl():S87-112. PubMed ID: 17274851
    [Abstract] [Full Text] [Related]

  • 6. Progress on vaccines against parasites.
    Engers HD, Bergquist R, Modabber F.
    Dev Biol Stand; 1996 Oct; 87():73-84. PubMed ID: 8854004
    [Abstract] [Full Text] [Related]

  • 7. Vaccine candidates for leishmaniasis: a review.
    Nagill R, Kaur S.
    Int Immunopharmacol; 2011 Oct; 11(10):1464-88. PubMed ID: 21616175
    [Abstract] [Full Text] [Related]

  • 8. Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice.
    Rafati S, Ghaemimanesh F, Zahedifard F.
    Vaccine; 2006 Apr 12; 24(16):3290-7. PubMed ID: 16481076
    [Abstract] [Full Text] [Related]

  • 9. Leishmaniasis.
    Kedzierski L.
    Hum Vaccin; 2011 Nov 12; 7(11):1204-14. PubMed ID: 22048116
    [Abstract] [Full Text] [Related]

  • 10. Vaccines in leishmaniasis: advances in the last five years.
    Brodskyn C, de Oliveira CI, Barral A, Barral-Netto M.
    Expert Rev Vaccines; 2003 Oct 12; 2(5):705-17. PubMed ID: 14711330
    [Abstract] [Full Text] [Related]

  • 11. Second-generation vaccines against leishmaniasis.
    Coler RN, Reed SG.
    Trends Parasitol; 2005 May 12; 21(5):244-9. PubMed ID: 15837614
    [Abstract] [Full Text] [Related]

  • 12. Immunomodulatory effects associated with a live vaccine against Leishmania major containing CpG oligodeoxynucleotides.
    Wu W, Weigand L, Belkaid Y, Mendez S.
    Eur J Immunol; 2006 Dec 12; 36(12):3238-47. PubMed ID: 17109471
    [Abstract] [Full Text] [Related]

  • 13. Vaccines for leishmaniasis in the fore coming 25 years.
    Palatnik-de-Sousa CB.
    Vaccine; 2008 Mar 25; 26(14):1709-24. PubMed ID: 18295939
    [Abstract] [Full Text] [Related]

  • 14. Recent advances in vaccines for leishmaniasis.
    Requena JM, Iborra S, Carrión J, Alonso C, Soto M.
    Expert Opin Biol Ther; 2004 Sep 25; 4(9):1505-17. PubMed ID: 15335317
    [Abstract] [Full Text] [Related]

  • 15. Recombinant DNA-derived leishmania proteins: from the laboratory to the field.
    Kubar J, Fragaki K.
    Lancet Infect Dis; 2005 Feb 25; 5(2):107-14. PubMed ID: 15680780
    [Abstract] [Full Text] [Related]

  • 16. Qualitative differences in the early immune response to live and killed Leishmania major: Implications for vaccination strategies against Leishmaniasis.
    Okwor I, Liu D, Uzonna J.
    Vaccine; 2009 Apr 28; 27(19):2554-62. PubMed ID: 19428861
    [Abstract] [Full Text] [Related]

  • 17. Development of vaccines against leishmaniasis.
    Modabber F.
    Scand J Infect Dis Suppl; 1990 Apr 28; 76():72-8. PubMed ID: 2102023
    [Abstract] [Full Text] [Related]

  • 18. [Future vaccines in parasitology].
    Lagardère B.
    Bull Soc Pathol Exot; 1991 Apr 28; 84(5 Pt 5):926-34. PubMed ID: 1819438
    [Abstract] [Full Text] [Related]

  • 19. CpG oligonucleotides as adjuvant in therapeutic vaccines against parasitic infections.
    Zimmermann S, Dalpke A, Heeg K.
    Int J Med Microbiol; 2008 Jan 28; 298(1-2):39-44. PubMed ID: 17716944
    [Abstract] [Full Text] [Related]

  • 20. Field trial of a vaccine against new world cutaneous leishmaniasis in an at-risk child population: how long does protection last?
    Armijos RX, Weigel MM, Romero L, Garcia V, Salazar J.
    J Infect Dis; 2003 Jun 15; 187(12):1959-61. PubMed ID: 12792873
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.